文献速递细菌感染、耐药与抗菌药物

成人反复尿路感染的持续低剂量抗生素预防(AnTIC):一项随机、开放标签试验

Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.
PubMed 文献 · Lancet Infect Dis · 2018-06-28

AnTIC 试验在 51 家英国国家医疗服务机构纳入 404 名社区成人清洁间歇自我导尿(CISC)使用者和反复尿路感染患者,1:1 随机分为每日一次抗生素预防组与不预防组,随访 12 个月。预防组症状性需抗生素治疗的尿路感染发生率为每人年 1.3 例(95%CI 1.1-1.6),对照组为 2.6 例(2.3-2.9),发生率比 0.52(0.44-0.61;p<0.0001),尿路感染频率降低 48%。预防耐受良好,但 9-12 个月时预防组尿分离菌对呋喃妥因、甲氧苄啶和复方磺胺甲噁唑的耐药更常见。

要点

  • 预防组尿路感染发生率为每人年 1.3 例,对照组 2.6 例,发生率比 0.52(p<0.0001)。
  • 9-12 个月时预防组尿分离菌对呋喃妥因、甲氧苄啶、复方磺胺甲噁唑耐药比例均高于对照组。
  • 预防组记录 22 例与抗生素预防相关的轻微不良事件,以胃肠道不适、皮疹、念珠菌感染为主。

核心结论

  • 对反复尿路感染的成人 CISC 使用者,持续抗生素预防可有效降低尿路感染频率且耐受良好,但尿菌耐药增加令人担忧,开始预防时需监测。

研究设计与样本

  • 随机、开放标签、优效性试验,纳入 51 家英国国家医疗服务机构的社区成人 CISC 使用者,1:1 随机分为每日一次抗生素预防组与不预防组,疗程 12 个月。
  • 2013 年 11 月 25 日至 2016 年 1 月 29 日筛查 1743 名成人 CISC 使用者,2013 年 11 月 26 日至 2016 年 1 月 31 日入组 404 人(23%),预防组 203 人(50%)、对照组 201 人(50%),随机前排除 1339 人。
  • 主要分析纳入预防组 181 人(89%)和对照组 180 人(90%);预防组 22 人、对照组 21 人因 6 个月前缺失随访数据未纳入。
  • 评估结局的试验与实验室人员对分组设盲,但参与者知晓治疗分组;主要结局为 12 个月内症状性、需抗生素治疗的尿路感染发生率。
  • 尿与粪便细菌抗菌药物耐药变化作为次要结局监测;试验注册号 ISRCTN 67145101、EudraCT 2013-002556-32。

主要发现

  • 12 个月内症状性需抗生素治疗的尿路感染发生率:预防组每人年 1.3 例(95%CI 1.1-1.6),对照组每人年 2.6 例(2.3-2.9),发生率比 0.52(95%CI 0.44-0.61;p<0.0001),预防使尿路感染频率降低 48%。
  • 预防组记录 22 例与抗生素预防相关的轻微不良事件,主要为胃肠道不适(6 人)、皮疹(6 人)和念珠菌感染(4 人)。
  • 9-12 个月时,预防组尿分离菌耐药比例高于对照组:呋喃妥因 12/51(24%)vs 6/64(9%),p=0.038;甲氧苄啶 34/51(67%)vs 21/64(33%),p=0.0003;复方磺胺甲噁唑 26/49(53%)vs 15/62(24%),p=0.002。

关键数值与推荐

  • 主要结局为 12 个月内症状性、需抗生素治疗的尿路感染发生率,分析仅纳入完成至少 6 个月随访的参与者。
  • 耐药分析比较 9-12 个月时至少有一次尿分离菌的参与者中耐药比例,预防组与对照组分别为呋喃妥因 24% vs 9%(p=0.038)、甲氧苄啶 67% vs 33%(p=0.0003)、复方磺胺甲噁唑 53% vs 24%(p=0.002)。

临床怎么用

  • 作者认为,对反复尿路感染的 CISC 使用者,持续抗生素预防可有效降低尿路感染频率且耐受良好。
  • 作者指出,尿菌耐药增加是开始预防时需监测的担忧。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Repeated symptomatic urinary tract infections (UTIs) affect 25% of people who use clean intermittent self-catheterisation (CISC) to empty their bladder. We aimed to determine the benefits, harms, and cost-effectiveness of continuous low-dose antibiotic prophylaxis for prevention of recurrent UTIs in adult users of CISC. METHODS: In this randomised, open-label, superiority trial, we enrolled participants from 51 UK National Health Service organisations. These participants were community-dwelling (as opposed to hospital inpatient) users of CISC with recurrent UTIs. We randomly allocated participants (1:1) to receive either antibiotic prophylaxis once daily (prophylaxis group) or no prophylaxis (control group) for 12 months by use of an internet-based system with permuted blocks of variable length. Trial and laboratory staff who assessed outcomes were masked to allocation but participants were aware of their treatment group. The primary outcome was the incidence of symptomatic, antibiotic-treated UTIs over 12 months. Participants who completed at least 6 months of follow-up were assumed to provide a reliable estimate of UTI incidence and were included in the analysis of the primary outcome. Change in antimicrobial resistance of urinary and faecal bacteria was monitored as a secondary outcome. The AnTIC trial is registered at ISRCTN, number 67145101; and EudraCT, number 2013-002556-32. FINDINGS: Between Nov 25, 2013, and Jan 29, 2016, we screened 1743 adult users of CISC for eligibility, of whom 404 (23%) participants were enrolled between Nov 26, 2013, and Jan 31, 2016. Of these 404 participants, 203 (50%) were allocated to receive prophylaxis and 201 (50%) to receive no prophylaxis. 1339 participants were excluded before randomisation. The primary analysis included 181 (89%) adults allocated to the prophylaxis group and 180 (90%) adults in the no prophylaxis (control) group. 22 participants in the prophylaxis group and 21 participants in the control group were not included in the primary analysis because they were missing follow-up data before 6 months. The incidence of symptomatic antibiotic-treated UTIs over 12 months was 1·3 cases per person-year (95% CI 1·1-1·6) in the prophylaxis group and 2·6 (2·3-2·9) in the control group, giving an incidence rate ratio of 0·52 (0·44-0·61; p<0·0001), indicating a 48% reduction in UTI frequency after treatment with prophylaxis. Use of prophylaxis was well tolerated: we recorded 22 minor adverse events in the prophylaxis group related to antibiotic prophylaxis during the study, predominantly gastrointestinal disturbance (six participants), skin rash (six participants), and candidal infection (four participants). However, resistance against the antibiotics used for UTI treatment was more frequent in urinary isolates from the prophylaxis group than in those from the control group at 9-12 months of trial participation (nitrofurantoin 12 [24%] of 51 participants from the prophylaxis group vs six [9%] of 64 participants from the control group with at least one isolate; p=0·038), trimethoprim (34 [67%] of 51 vs 21 [33%] of 64; p=0·0003), and co-trimoxazole (26 [53%] of 49 vs 15 [24%] of 62; p=0·002). INTERPRETATION: Continuous antibiotic prophylaxis is effective in reducing UTI frequency in CISC users with recurrent UTIs, and it is well tolerated in these individuals. However, increased resistance of urinary bacteria is a concern that requires surveillance if prophylaxis is started. FUNDING: UK National Institute for Health Research.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Fisher H, Oluboyede Y, Chadwick T, et al. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. Lancet Infect Dis. 2018. PMID: 30037647. doi:10.1016/S1473-3099(18)30279-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。